After much heralding, MIFID II is finally beginning to have an impact on the business of investment research, though its true ramifications might take years to be seen. The role of analyst research is widely misunderstood. It is not all about the conclusion: the rating and price target. The real content of research is about what is discounted in the current share price and what assumptions would produce different outcomes.

03 Apr 2017
The Monthly
Abzena (ABZA:LON), 0 | Allergy Therapeutics plc (AGY:LON), 7.6 | Arbuthnot Banking Group PLC (ARBB:LON), 955 | Avacta Group PLC (AVCT:LON), 30.0 | Burford Capital Limited (BUR:LON), 948 | Cambridge Cognition Holdings Plc (COG:LON), 32.0 | City of London Investment Group PLC (CLIG:LON), 348 | TheraCryf PLC (TCF:LON), 0.3 | Murgitroyd Group (MUR:LON), 0 | Cambridge Nutritional Sciences PLC (CNSL:LON), 3.8 | PPHE Hotel Group Limited (PPH:LON), 1,633 | Primary Health Properties PLC (PHP:LON), 98.1 | R.E.A. Holdings plc (RE:LON), 85.0 | Scancell Holdings Plc (SCLP:LON), 9.5 | Sinclair Pharma (SPH:LON), 0 | Tissue Regenix Group plc (TRX:LON), 28.5 | Oxford BioMedica plc (OXB:LON), 318

Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
The Monthly
Abzena (ABZA:LON), 0 | Allergy Therapeutics plc (AGY:LON), 7.6 | Arbuthnot Banking Group PLC (ARBB:LON), 955 | Avacta Group PLC (AVCT:LON), 30.0 | Burford Capital Limited (BUR:LON), 948 | Cambridge Cognition Holdings Plc (COG:LON), 32.0 | City of London Investment Group PLC (CLIG:LON), 348 | TheraCryf PLC (TCF:LON), 0.3 | Murgitroyd Group (MUR:LON), 0 | Cambridge Nutritional Sciences PLC (CNSL:LON), 3.8 | PPHE Hotel Group Limited (PPH:LON), 1,633 | Primary Health Properties PLC (PHP:LON), 98.1 | R.E.A. Holdings plc (RE:LON), 85.0 | Scancell Holdings Plc (SCLP:LON), 9.5 | Sinclair Pharma (SPH:LON), 0 | Tissue Regenix Group plc (TRX:LON), 28.5 | Oxford BioMedica plc (OXB:LON), 318
- Published:
03 Apr 2017 -
Author:
Jason Street -
Pages:
36 -
After much heralding, MIFID II is finally beginning to have an impact on the business of investment research, though its true ramifications might take years to be seen. The role of analyst research is widely misunderstood. It is not all about the conclusion: the rating and price target. The real content of research is about what is discounted in the current share price and what assumptions would produce different outcomes.